Kiniksa and Huadong Medicine $22M upfront Asia Pacific deal; ARCALYST FY2022 rev guidance $115-130M

Kiniksa Pharmaceuticals International, plc

Upfront $22M from Huadong; up to $640M milestones + low-teens to low-twenties royalties on net sales for ARCALYST and mavrilimumab in Asia Pacific (ex-Japan).
ARCALYST net revenue $18.7M Q4 2021, $38.5M FY2021; collaboration achieved profitability in Q4.
FY2022 ARCALYST net revenue guidance $115-130M; cash $182.2M, no debt, funded into 2024.
No Phase 3 for mavrilimumab in giant cell arteritis; vixarelimab Phase 2b data in prurigo nodularis expected H2 2022.
Net loss $36.3M Q4 2021 vs $53.7M Q4 2020; full-year net loss $157.9M vs $161.4M in 2020.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.